Outi Lahdenperä

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer

Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen et al. · JAMA Oncology · 2017 · 95 citations · Full text

Medicine, Oncology, Pharmacology +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer

Leena Tiainen, Mari Hämäläinen, Tiina Luukkaala et al. · Clinical Breast Cancer · 2019 · 52 citations · Full text

Medicine, Immunology, Oncology +15

Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer

Leena Tiainen, Minna Tanner, Outi Lahdenperä et al. · Anticancer Research · 2016 · 24 citations · Full text

Medicine, Oncology, Pharmacology +15

High baseline Tie1 level predicts poor survival in metastatic breast cancer

Leena Tiainen, Emilia A. Korhonen, Veli‐Matti Leppänen et al. · BMC Cancer · 2019 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17